Shots: Takeaways: Sevmia’s approval makes Apotex the first Canadian generic challenger in Wegovy, which should increase price competition, widen access to semaglutide for ch...
Takeaways: Vimkunya’s Health Canada approval turns Bavarian Nordic’s chikungunya shot into a genuinely global travel-vaccine franchise, which should drive uptake in Canadian travel cl...
Takeaways: Boey gives Allergan Aesthetics a differentiated entry point in Canadian aesthetics: a fast-onset, short-duration botulinum option that can attract first-time or co...
Takeaways: The new products expand Organon’s Canadian biosimilars line to eight drugs across five therapeutic areas, including oncology, strengthening its position as a major biosimilar sup...
Takeaways: This approval strengthens Lilly’s competitive stance against other GLP-1/GIP agents in the obesity space by adding a disease-specific indication (OSA) that ties directl...
Takeaways: Exdensur positions GSK as the first biologic in Canada with twice-yearly dosing for severe eosinophilic asthma, a major convenience advantage over existing IL‑4/5...
Takeaways: Shortening Breyanzi’s required stay-near-centre period and driving ban lowers the logistical and financial barriers to CAR T, which should modestly expand the eligible treat...
Real world evidence (RWE) is rapidly reshaping how therapies are evaluated, approved, and commercialized within global healthcare systems, including Canadian Health. Derived from real world data such ...
Takeaways: Roche’s dual-formulation (IV and SC) authorization for Lunsumio (mosunetuzumab) in Canada creates flexible, fixed-duration access for relapsed/refractory follicular lymphoma...
Takeaways: Health Canada’s decision makes Nucala the first biologic add‑on for eosinophilic COPD in Canada, opening a new high-value segment on top of triple inhaled therapy for patients with fr...
